Navigation Links
Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
Date:7/29/2010

tatements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the anticipated action date for the FDA to complete its review of the Contrave NDA, the potential for, and timing of, approval for Contrave and the Company's belief that this product candidate may be an important therapeutic option in the treatment of obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the uncertainty of the FDA approval process and other regulatory requirements; the therapeutic and commercial value of Contrave; reliance on third parties to assist with the development of Contrave; the potential for adverse safety findings relating to Contrave; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 10, 2010 and is available from
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 Roche,s Bloodhound ... high-growth market segment in hematology testing, according to ... that Roche,s recent unveiling of its Bloodhound digital cell ... cobas m 511 hematology analyzer – is ... growth enjoyed by current leader CellaVision, but also ...
(Date:7/2/2015)... July 2, 2015  The Green Exchange, Inc., the ... first HIPAA compliant mobile app that connects cannabis growers ... medical marijuana, announced today that their service provides the ... Meadow and more than half a dozen other delivery ... Loud Cannabis is unique in that it connects ...
(Date:7/2/2015)... 2015 The report "Silage Inoculants ... (Lactobacillus, Pediococcus & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type ... Silage Inoculants & Enzymes Market is expected to reach ... from 2015 to 2020. Browse 75 ... 194 P ages and an in-depth ...
Breaking Medicine Technology:Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in ... Avimex distributes biological and pharmaceutical products for use in ... world. Avimex is providing financial support for the ...
... , SHENYANG, China, Oct. 20 ... "Company"), a leading China-based biotechnology,company focused on researching, developing, ... its annual general,meeting of shareholders held on October 12, ... the Company,s shareholders re-elected Dr. Jing Lou and Mr.,Moujia ...
Cached Medicine Technology:Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 2Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 3Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 4Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico 5
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... First ... United States, named Mariah N. Manzanares, MD as the new Medical Director of its ... facility medical director of our Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:7/3/2015)... Deer, Alberta (PRWEB) , ... July 03, 2015 , ... ... host their 24-Hour Train-a-Thon where they provide members of the Red Deer community with ... year’s full day of fitness training, games, food, events and entertainment raised thousands of ...
(Date:7/2/2015)... Richmond, VA (PRWEB) , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased ... the 18th sweetFrog store located in the Lone Star State. The premium frozen yogurt chain ... , The store, which opened June 19 in the Village at Bachman Lake, is located ...
(Date:7/2/2015)... ... 2015 , ... The American Association of Poison Control Centers ... Stat (S.O.S.) Act of 2015 on June 23, 2015. Together with the Senate ... drug overdose – especially of heroin and opioid medication – by expanding the ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... With summer in full swing, Americans are ... is one of the top spots for fishing in the world, and it’s easy to ... of Ontario, Canada has great fish. , Recreational fishing is a huge industry, and ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3
... concept catching up fast in the West. ,With the ... phones with hundreds of names and numbers stored in its ... these numbers belong to the near and dear. ,In ... had a heart attack and the physicians attending on the injured ...
... La Jolla Institute for Allergy & Immunology (LIAI) made ... new therapeutic approach for treating autoimmune and inflammatory diseases ... ,.The studies, conducted in laboratory mice, demonstrated ... Vitamin A is broken down in the body, in ...
... Yarra River, posing serious threat to wildlife in the region ... the water until the slick - from the Chandler Highway ... ,The Environment Protection Agency (EPA) is investigating the source of ... was not discovered until Tuesday by a kayaker using the ...
... the University of Illinois at Chicago and Cornell University ... in patients who suffer from Neurodegenerative diseases or stroke ... cellular events take place that lead to the death ... enzymes called histone deacetylases can modulate gene expression, and ...
... revealed that drug letrozole, which is used to treat breast ... from Ovarian cancer by three years. ,The researcher used ... ,Though the discovery may not benefit all because not ... silent killer are triggered by oestrogen, it still offers hope ...
... The Chandigarh administration, planning to make the city 'smoke-free' from ... ,At a meeting of the committee set up to ... city, it was decided to empower police officials of the ... public places by recovering the penalty from the offender on ...
Cached Medicine News:Health News:Look Out for ICE in Emergency Situations 2Health News:New Therapeutic Approach for Autoimmune and Inflammatory Diseases 2Health News:Australia Battles Oil Slick on Yarra River 2Health News:Researchers Developing New Therapy to Re-activate Silenced Genes 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: